Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cost-Effective Use of Bisphosphonates in Metastatic Bone Disease - A Comparison of Bone Marker Directed Zoledronic Acid Therapy to a Standard Schedule

NCT00458796 is registered in ClinicalTrials.gov with University of Leeds as lead sponsor.

NCT NCT00458796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00458796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cost-Effective Use of Bisphosphonates in Metastatic Bone Disease - A Comparison of Bone Marker Directed Zoledronic Acid Therapy to a Standard Schedule
Lead sponsor
University of Leeds
Phase
Not applicable
Overall status
Terminated
Start date
March 31, 2006
Completion date
Not reported
Enrollment
1,500 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hypercalcemia of malignancy, metastatic cancer, musculoskeletal complications, pain